SINGLE-CELL RNA SEQUENCING OF LYMPHOCYTE SUBSETS AND CHOLANGIOCYTES IN NON-ENDSTAGE PSC PATIENTS

SINGLE-CELL RNA SEQUENCING OF LYMPHOCYTE SUBSETS AND CHOLANGIOCYTES IN NON-ENDSTAGE PSC PATIENTS - Single cell RNAseq in PSC (SCRIPT)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51642

Enrollment

Registered

2023-01-09

Start date

2023-02-07

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primairy sclerosing cholangitis PSC

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Cases: - established diagnosis of large duct PSC and concurrent inflammatory bowel disease. - Patients should be able to give written informed consent - age >=18 year - Child-Pugh-Turcott score =18 year

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Cases: - signs of bacterial cholangitis - mandatory anticoagulation Controls: - signs of bacterial cholangitis - mandatory anticoagulation

Design outcomes

Secondary

Measure	Time frame
1. To characterize immune cell subsets between peripheral blood of PSC patients and compare these to the bile duct derived subsets in relation to samples taken from healthy bileduct epithelium. 2. To align the outcome of this transcriptomic analysis with known drug target genes. 3. To align the outcome of this transcriptome analysis with previously identified inflammatory patterns in the colon of IBD patients with and without PSC	—

Measure

Time frame

1. To characterize immune cell subsets between peripheral blood of PSC patients and compare these to the bile duct derived subsets in relation to samples taken from *healthy* bileduct epithelium. 2. To align the outcome of this transcriptomic analysis with known drug target genes. 3. To align the outcome of this transcriptome analysis with previously identified inflammatory patterns in the colon of IBD patients with and without PSC

—

Primary

Measure	Time frame
To characterize the disease specific composition and activity of immune cell subsets and cholangiocytes in active inflammation in the central/extrahepatic bile ducts of PSC patients and normal bileduct tissue using surface markers and in-depth transcriptomic analysis.	—

Countries

Netherlands

Outcome results